Company Overview - Climb Bio, Inc. is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases [2] - The company's pipeline includes budoprutug, an anti-CD19 monoclonal antibody, which has shown B-cell depletion and potential to treat various B-cell mediated diseases [2] - Another key product in development is CLYM116, an anti-APRIL monoclonal antibody currently undergoing IND-enabling studies for IgA nephropathy [2] Upcoming Investor Conferences - Climb Bio's executive team will participate in the TD Cowen 45 Annual Health Care Conference on March 4, 2025, at 9:50 a.m. ET, featuring formal presentations and one-on-one investor meetings [2] - The company will also be present at Leerink's Global Healthcare Conference 2025 on March 10, 2025, at 10:00 a.m. ET, which will include a fireside chat and one-on-one investor meetings [2]
Climb Bio to Present at Upcoming Investor Conferences